Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02221830 · ClinicalTrials.gov registry record · Early Phase 1
Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)
A Early Phase 1 study of Preeclampsia, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 66
- Enrollment target
- 1
- Study location
NCT02221830: Completed Early Phase 1 study of Preeclampsia, sponsored by University of Colorado, Denver.
NCT02221830 is a Early Phase 1 study of Preeclampsia that has completed, run by University of Colorado, Denver. The registered enrollment target is 66 participants, below the 1,125-participant average among 48 other Preeclampsia trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02221830, a Early Phase 1 study of Preeclampsia, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluation of the efficacy of postpartum 24 hour oxytocin infusion to reduce blood loss in patients with pre-eclampsia (PE)
Primary Outcome
Postpartum hematocrit (collected 24 hours after delivery unless patient receives blood transfusion, then pre-transfusion hematocrit will be used)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Oxytocin
Study Locations (1)
Colorado
- University of Colorado Clinical and Translational Research Center - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-02 |
| Est. Completion | 2019-07-17 |
| Phase | Early Phase 1 |
What the finished NCT02221830 record still lists
NCT02221830 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 1,125-participant average among 48 other Preeclampsia trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Preeclampsia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02221830 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT02221830 about?
NCT02221830 is a clinical study titled "Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)". Evaluation of the efficacy of postpartum 24 hour oxytocin infusion to reduce blood loss in patients with pre-eclampsia (PE)
What is the current status of trial NCT02221830?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 66 participants. The study started on 2015-02. Estimated completion is 2019-07-17.
What conditions does trial NCT02221830 study?
This clinical trial studies the following conditions: Preeclampsia.
What interventions are being tested in trial NCT02221830?
The interventions under investigation include: Placebo (DRUG), Oxytocin (DRUG).
Who is sponsoring clinical trial NCT02221830?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02221830 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02221830's enrollment target sits among peer trials
66 34th of 48 higher than 14 of 48 other Preeclampsia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Preeclampsia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Daily Aspirin Treatment After Preeclampsia
RECRUITING · Early Phase 1
-
Prenatal Aspirin and Postpartum Vascular Function
RECRUITING · Early Phase 1
-
Predictors of Aspirin Failure in Preeclampsia Prevention
RECRUITING · Early Phase 1
-
Vascular Effects of High-Salt After Preeclampsia
RECRUITING · Early Phase 1
-
MR and Inflammation After Preeclampsia
ACTIVE NOT RECRUITING · Early Phase 1
-
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia